Director's Dealing

RNS Number : 8826W
Avacta Group PLC
29 April 2016
 

29 April 2016

 

Avacta Group plc

("Avacta" or "the Group" or "the Company")

 

Director's Dealing

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that Craig Slater, Chief Operating Officer of the Group, has today purchased 2,222 Ordinary Shares of 10p each in the Group at a price of 112.5 pence per share.

 

Following this transaction, Mr Slater's total interest in the Group is 349,452 Ordinary Shares of 10p each, representing approximately 0.5% of Avacta's issued share capital.

 

 

Enquiries:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

 

Tel:  +44 (0) 844 414 0452

www.avacta.com

Numis Securities Limited    

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking

Tel:  +44 (0) 207 260 1000

www.numiscorp.com

WG Partners

David Wilson

Nigel Barnes

Claes Spang

Tel:  +44 (0) 203 705 9318

Tel:  +44 (0) 203 705 9217

www.wgpartners.co.uk

 

Media Enquiries

FTI Consulting

Simon Conway / Natalie Garland-Collins

Tel: +44 (0) 203 727 1000

avacta@fticonsulting.com

 

Notes to Editors

 

Avacta Group plc (www.avacta.com)

 

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

 

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

 

Avacta has a pre-clinical biotech development programme with an in-house focus on oncology and bleeding disorders as well as several partnered development programmes. Avacta is commercialising Affimer reagents through custom Affimer services to provide bespoke solutions to customers and via a growing on-line catalogue of Affimer reagents.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFISSLIAFIR
UK 100

Latest directors dealings